SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

ABV-1601

ABVC·ABVC BIOPHARMA, INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase I
Time to market
Very distant; the drug is in early Phase I with no publicly reported enrollment or results since the site initiation visit in March 2023. Assuming successful Phase I, Phase II, and Phase III trials, potential approval would be many years away.
Why 2/10
No hard dated catalyst is scheduled in the next ~12 months. The drug completed a Phase I site initiation visit in March 2023 at Cedars-Sinai Medical Center for depression in cancer patients, but no subsequent topline readout, PDUFA date, or pivotal trial start has been publicly announced. The program appears to be a very early-stage, low-priority asset within a small-cap company that has multiple other pipeline candidates (ABV-1504, ABV-1505) and is pursuing a spin-off of its BioKey subsidiary.
Actionable Insight NEUTRAL

Watch for any ABVC press release or SEC filing mentioning advancement of ABV-1601 into patient enrollment or a Phase I data readout. The company's near-term value drivers appear to be its later-stage CNS candidates (ABV-1504/ABV-1505 for MDD/ADHD) and the planned BioKey spin-off, not ABV-1601.

Price Chart

Loading chart...

Executive Summary

ABV-1601 is an early-stage Phase I drug candidate from ABVC BioPharma (NASDAQ: ABVC), a clinical-stage company focused on botanical-derived therapeutics for CNS, ophthalmology, and oncology. The drug is being studied for treating depression in cancer patients. The only public clinical milestone was a Phase I site initiation visit at Cedars-Sinai Medical Center in March 2023. No patient enrollment, dosing data, or results have been reported since, and no upcoming catalysts are scheduled. ABV-1601 appears to be a minor, early-stage program within a company whose more advanced pipeline (ABV-1504/ABV-1505 for major depressive disorder and ADHD) and corporate restructuring (BioKey spin-off) are the primary value drivers.

How It Works

ABV-1601 is described as a medication for treating depression in cancer patients. Based on ABVC's broader pipeline focus on botanical-derived therapeutics, it is likely a plant-based or natural compound targeting central nervous system (CNS) disorders, but the specific mechanism of action has not been publicly detailed.

Trial Status

The Cedars-Sinai Medical Center IRB approved site participation in November 2022 for a Phase I study of ABV-1601 treating depression in cancer patients. A site initiation visit (SIV) was successfully conducted on March 31, 2023. No subsequent updates on patient enrollment, dosing, or results have been publicly reported as of November 2026.

The Two-Sided Case

▲ Bull Case3
ABV-1601 targets an unmet need: depression in cancer patients, a large and underserved patient population.
The drug is part of ABVC's botanical-derived pipeline, which could offer a differentiated safety profile versus conventional antidepressants.
Cedars-Sinai Medical Center's participation lends credibility to the clinical program.
▼ Bear Case5
No public update on ABV-1601 since the April 2023 site initiation visit, suggesting the program may be paused, deprioritized, or struggling to enroll patients.
ABVC is a micro-cap stock (market cap ~$28M, stock price ~$0.91) with significant financing dilution risk, having recently closed a $3.39M convertible note offering.
The company has multiple higher-priority programs (ABV-1504, ABV-1505, BioKey spin-off), making ABV-1601 a likely low-priority asset.
No analyst coverage, no institutional consensus, and a negative quant composite score (-32) indicate low market interest.
The drug is very early stage (Phase I) with no clear path to commercialization for years, if ever.

Upcoming Catalysts

  • No scheduled catalysts identified for ABV-1601 specifically. Watch for any ABVC press release on pipeline advancement, patient enrollment, or Phase I data for ABV-1601.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report

Sources · 5

Hover a chip for the title
1 nasdaq.com2 theglobeandmail.com3 theglobeandmail.com4 zonebourse.com5 marketscreener.com